Tumor cell membranes and surface glycosylated molecules

Tumor cell membranes and surface glycosylated molecules represent a broad category of structural and functional components that undergo significant alterations during oncogenesis. The cancer cell surface is characterized by an aberrant glycocalyx, featuring overexpressed or truncated glycans known as tumor-associated carbohydrate antigens (TACAs), such as GD2, Sialyl-Lewis X, and various mucins (Pinho & Reis, 2015, Nature Reviews Cancer). These molecules play critical roles in mediating cell-cell adhesion, promoting metastasis through selectin binding, and facilitating immune evasion by interacting with inhibitory receptors like Siglecs on immune cells (Pearce et al., 2018, Glycobiology). Additionally, the lipid composition of the tumor membrane often shifts, such as the externalization of phosphatidylserine, providing unique docking sites for therapeutic agents (Birge et al., 2016, Cell Death & Differentiation). Therapeutic strategies targeting these surface structures include monoclonal antibodies, antibody-drug conjugates, and CAR-T cells designed to recognize specific glyco-epitopes. While highly promising for precision oncology, the complexity and heterogeneity of glycosylation across different tumor types present significant challenges for universal targeting and safety (Munkley & Elliott, 2016, Oncotarget).

Other names

Tumor cell surfaceCancer cell glycocalyxTumor-associated carbohydrate antigens (TACAs)Tumor-associated glycansCancer cell membrane

Drugs targeting these molecules typically act through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or by blocking glycan-mediated signaling and immune checkpoint interactions to restore anti-tumor immunity.